Read by QxMD icon Read

Lenalidomide AND lymphoma

Ya-Ting Yang, Cheng-Jeng Tai, Chiehfeng Chen, Hong-Cheng Wu, Natalia Mikhaylichenko, Hsien-Tsai Chiu, Yun-Yi Chen, Yi-Hsin Elsa Hsu
BACKGROUND: The goal of this study was to perform a systematic review to examine the efficacy and safety of various salvage therapy regimens on patients with relapsed/refractory PTCL. METHOD: The electronic searches were performed using PubMed, Cochrane Library, EMBASE, and Web of Science from inception through June 2015, with search terms related to relapsed/refractory PTCL, salvage chemotherapy regimens, and clinical trials. An eligible study met the following inclusion criteria: (1) Patients had refractory or relapsed PTCL; (2) drug regimens were used for salvage therapy; (3) the study was a clinical trial; (4) the study reported on a series of at least 10 patients of PTCL...
2016: PloS One
Chaitra S Ujjani, Sin-Ho Jung, Brandelyn Pitcher, Peter Martin, Steven I Park, Kristie A Blum, Sonali M Smith, Myron Czuczman, Matthew S Davids, Ellis Levine, Lionel D Lewis, Scott E Smith, Nancy L Bartlett, John P Leonard, Bruce D Cheson
Chemoimmunotherapy in follicular lymphoma is associated with significant toxicity. Targeted therapies are being investigated as potentially more efficacious and tolerable alternatives for this multiply-relapsing disease. Based on promising activity with rituximab and lenalidomide in previously untreated follicular lymphoma (ORR 90-96%) and ibrutinib in relapsed disease (ORR 30-55%), the Alliance for Clinical Trials in Oncology conducted a phase I trial of rituximab, lenalidomide, and ibrutinib. Previously untreated patients with follicular lymphoma received rituximab 375 mg/m(2) on Day 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycle 4, 6, 8, 10, lenalidomide as per cohort dose on Days 1-21/28 for 18 cycles, and ibrutinib as per cohort dose daily until progression...
October 3, 2016: Blood
Takashi Ishida, Hiroshi Fujiwara, Kisato Nosaka, Naoya Taira, Yasunobu Abe, Yoshitaka Imaizumi, Yukiyoshi Moriuchi, Tatsuro Jo, Kenichi Ishizawa, Kensei Tobinai, Kunihiro Tsukasaki, Shigeki Ito, Makoto Yoshimitsu, Maki Otsuka, Michinori Ogura, Shuichi Midorikawa, Wanda Ruiz, Tomoko Ohtsu
PURPOSE: Few treatment options exist for adult T-cell leukemia/lymphoma (ATL), and the prognosis for this disease is poor. A phase I study of lenalidomide demonstrated preliminary antitumor activity in patients with relapsed ATL. The current phase II study evaluated the efficacy and safety of lenalidomide monotherapy in patients with relapsed or recurrent ATL. PATIENTS AND METHODS: Patients 20 years of age or older with acute, lymphoma, or unfavorable chronic subtype ATL, who had received one or more prior anti-ATL systemic chemotherapy and achieved stable disease or better on their last anti-ATL therapy with subsequent relapse or recurrence, were eligible...
September 12, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Kensei Tobinai
Recent clinical trials for T/NK-cell lymphomas are summarized herein, focusing on ATL and extranodal NK/T-cell lymphoma (ENKL). The outcomes of patients with these malignancies were the poorest among various peripheral T-cell lymphomas (PTCLs) in the International T-Cell Lymphoma Project. JCOG has conducted several clinical trials aimed at improving these poor outcomes. For aggressive ATL, JCOG is conducting a phase II trial of VCAP-AMP-VECP followed by allogeneic SCT. For localized ENKL, concurrent chemoradiotherapy has shown promising and durable efficacy in the phase I/II study...
August 2016: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
Jonathan M Loree, Ellen Cai, Brandon S Sheffield, Jan P Dutz, Diego Villa, Lois E Shepherd, Joseph M Connors, Laurie H Sehn, Kerry J Savage
No abstract text is available yet for this article.
August 25, 2016: Leukemia & Lymphoma
Marc Sorigue, Josep-Maria Ribera, Cristina Motlló, Juan-Manuel Sancho
Despite the improvement in prognosis since the advent of rituximab, follicular lymphoma is still incurable and remains the cause of death of most afflicted patients. With the expanding knowledge of the pathogenesis of B-cell malignancies, in the last few years a plethora of new therapies acting through a variety of mechanisms have shown promising results. This review attempts to analyze the evidence available on these new drugs, which include new monoclonal antibodies and immunoconjugates, the anti-angiogenic and immunomodulatory agent lenalidomide, the proteasome inhibitor bortezomib, inhibitors of B-cell receptor pathway enzymes, such as ibrutinib, idelalisib, duvelisib and entospletinib, BCL2 inhibitors and checkpoint inhibitors...
October 2016: Leukemia Research
Mili Arora, Sonia Gowda, Joseph Tuscano
Lenalidomide, an immunomodulatory drug that the US Food and Drug Administration (FDA) approved for the treatment of multiple myeloma, 5q- myelodysplasia and mantle-cell lymphoma (MCL), has encouraging efficacy in other B-cell malignancies. Its unique mechanism of action is in part due to altering the tumor microenvironment and potentiating the activity of T and natural-killer (NK) cells. Impressive clinical activity and excellent tolerability allows broad applicability. Lenalidomide has been used in a wide range of B-cell malignancies for years, but in 2013, the FDA marked its approval as a single agent only in relapsed/refractory mantle-cell lymphoma...
August 2016: Therapeutic Advances in Hematology
Sylvain Garciaz, Diane Coso, Jean-Marc Schiano de Colella, Réda Bouabdallah
INTRODUCTION: Although the combination of an anti-CD20 monoclonal antibody and chemotherapy has widely improved survival of patients with B-cell lymphoma, the disease still relapses. A better understanding of the biology of lymphomas has highlighted the role of the cell of origin in response to treatment and outcome. Lenalidomide represents an attractive therapeutic option due to its original mechanism of action. AREAS COVERED: In this review, the authors describe the pharmacological properties of lenalidomide, and the rational for its use in B-cell lymphomas; focusing on diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL)...
September 2016: Expert Opinion on Investigational Drugs
Patrizia Mondello, Normann Steiner, Wolfgang Willenbacher, Simone Ferrero, Paola Ghione, Alessandra Marabese, Vincenzo Pitini, Salvatore Cuzzocrea, Michael Mian
BACKGROUND: Despite the advent of new treatment strategies, many patients with diffuse large B-cell lymphoma (DLBCL) relapse or die of the disease. Prospective clinical trials have demonstrated that lenalidomide is an effective and safe treatment option, especially for non-germinal center B-cell (non-GCB) DLBCL. However, routine clinical data are lacking, which is why we provide the results of the so-far largest relapsed/refractory (R/R) DLBCL real-life analysis. METHODS: We retrospectively assessed 123 R/R DLBCL patients who received either 15 or 25 mg/day of lenalidomide from January 2006 to January 2015...
September 2016: Oncologist
Alexandra Albertsson-Lindblad, Arne Kolstad, Anna Laurell, Riikka Räty, Kirsten Grønbæk, Jan Sundberg, Lone Bredo Pedersen, Elisabeth Ralfkiær, Marja-Liisa Karjalainen-Lindsberg, Christer Sundström, Mats Ehinger, Christian Geisler, Mats Jerkeman
For elderly patients with mantle cell lymphoma (MCL), there is no defined standard therapy. In this multicenter open-label phase I/II trial we evaluated the addition of lenalidomide (LEN) to rituximab-bendamustine (R-B) as first-line treatment to elderly MCL patients. Patients >65 years with untreated MCL, stage II-IV were eligible for inclusion. Primary endpoints were maximally tolerable dose (MTD) of LEN, and progression-free survival (PFS). Patients received six cycles q4w of L-B-R (L D1-14, B 90 mg/m(2) iv D1-2 and R 375 mg/m(2) iv D1) followed by single LEN (D1-21, q4w, cycles 7-13)...
June 27, 2016: Blood
Takumi Sugimoto, Takashi Watanabe
The microenvironment of follicular lymphoma (FL) is composed of tumor-infiltrating CD8(+) T cells, follicular regulatory T cells, lymphoma-associated macrophages and mast cells, follicular helper T cells, follicular dendritic cells, and follicular reticular cells, all of which have been reported to have relevance in the prognosis of FL patients. In addition, some of these cells play a role in the histologic transformation of FL. Macrophages contribute to a poor prognosis in FL patients treated in the pre-rituximab era, but are associated with good prognosis in those treated in the rituximab era...
2016: Journal of Clinical and Experimental Hematopathology: JCEH
Massimiliano Salati, Vittoria Tarantino, Antonino Maiorana, Stefania Bettelli, Stefano Luminari
Secondary central nervous system involvement is an uncommon event that typically occurs early in the natural history of diffuse large B-cell lymphoma and presents as leptomeningeal dissemination in two-thirds of cases. The prognosis of this event is dismal, and treatment options are meagre. Although major validated risk factors for central nervous system dissemination are clinical, concomitant MYC/BCL2 rearrangements as well as MYC/BCL2 protein expression have been recently associated with an increased risk of this complication...
June 15, 2016: Hematological Oncology
Richard J Jones, Tawin Iempridee, Xiaobin Wang, Hans C Lee, Janet E Mertz, Shannon C Kenney, Heather C Lin, Veerabhadran Baladandayuthapani, Christopher W Dawson, Jatin J Shah, Donna M Weber, Robert Z Orlowski
PURPOSE: Lenalidomide, thalidomide, and pomalidomide (LTP) are immunomodulatory agents approved for use in multiple myeloma, but in some settings, especially with alkylating agents, an increase in Hodgkin lymphoma and other secondary primary malignancies (SPM) has been noted. Some of these malignancies have been linked to Epstein-Barr virus (EBV), raising the possibility that immunomodulatory drugs disrupt latent EBV infection. EXPERIMENTAL DESIGN: We studied the ability of LTP to reactivate latently infected EBV-positive cell lines in vitro and in vivo, and evaluated the EBV viral load in archived serum samples from patients who received a lenalidomide, thalidomide, and dexamethasone (LTD) combination...
October 1, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Pier Luigi Zinzani, Luigi Rigacci, Maria Cristina Cox, Liliana Devizzi, Alberto Fabbri, Francesco Zaja, Alice Di Rocco, Giuseppe Rossi, Sergio Storti, Pier Paolo Fattori, Lisa Argnani, Umberto Vitolo
No abstract text is available yet for this article.
June 2, 2016: Leukemia & Lymphoma
Pier Luigi Zinzani, Cinzia Pellegrini, Lisa Argnani, Alessandro Broccoli
No abstract text is available yet for this article.
September 2016: Haematologica
Adrian Tempescul, Jean-Christophe Ianotto, Cristina Bagacean, Pierre-Yves Salaun, Corina Bocsan, Mihnea Zdrenghea
Mantle cell lymphoma is a hematologic malignancy characterized by poor therapeutic outcomes. Immunomodulatory drugs are a focus of attention in this disease, especially for the elderly and frail patients not able to tolerate the typically intensive therapeutic approaches used in fitter patients. We here present the case of refractory mantle cell lymphoma of the elderly that achieved complete remission following the use of single-agent lenalidomide, and a second complete response to the same regimen on relapse 5 years later...
September 2016: International Journal of Hematology
Chenglin Wu, Noel Fcc de Miranda, Longyun Chen, Agata M Wasik, Larry Mansouri, Wojciech Jurczak, Krystyna Galazka, Monika Dlugosz-Danecka, Maciej Machaczka, Huilai Zhang, Roujun Peng, Ryan D Morin, Richard Rosenquist, Birgitta Sander, Qiang Pan-Hammarström
The genetic mechanisms underlying disease progression, relapse and therapy resistance in mantle cell lymphoma (MCL) remain largely unknown. Whole-exome sequencing was performed in 27 MCL samples from 13 patients, representing the largest analyzed series of consecutive biopsies obtained at diagnosis and/or relapse for this type of lymphoma. Eighteen genes were found to be recurrently mutated in these samples, including known (ATM, MEF2B and MLL2) and novel mutation targets (S1PR1 and CARD11). CARD11, a scaffold protein required for B-cell receptor (BCR)-induced NF-κB activation, was subsequently screened in an additional 173 MCL samples and mutations were observed in 5...
May 20, 2016: Oncotarget
R M Santi, M Ceccarelli, G Catania, C Monagheddu, A Evangelista, E Bernocco, F Monaco, M Federico, U Vitolo, S Cortelazzo, M G Cabras, M Spina, L Baldini, C Boccomini, A Chiappella, A Bari, S Luminari, M Calabrese, A Levis, C Visco, L Contino, G Ciccone, M Ladetto
BACKGROUND: Recent studies show that the risk of VTE in NHL pts is similar to that observed in high risk solid tumors (i.e. pancreatic, ovarian cancer). VTE in NHL occurs in most cases within three months from diagnosis and can have substantial impact on treatment delivery and outcome as well as on quality of life. However few data are available on potential predictors. AIMS: To better clarify the epidemiology of early (within six months from treatment start) VTE in NHL we conducted a pooled data analysis of 12 clinical trials from FIL...
April 2016: Thrombosis Research
Pavel Otáhal, Dana Průková, Vlastimil Král, Milan Fabry, Petra Vočková, Lucie Latečková, Marek Trněný, Pavel Klener
Tumor immunotherapy based on the use of chimeric antigen receptor modified T cells (CAR T cells) is a promising approach for the treatment of refractory hematological malignancies. However, a robust response mediated by CAR T cells is observed only in a minority of patients and the expansion and persistence of CAR T cells in vivo is mostly unpredictable.Lenalidomide (LEN) is an immunomodulatory drug currently approved for the treatment of multiple myeloma (MM) and mantle cell lymphoma, while it is clinically tested in the therapy of diffuse large B-cell lymphoma of activated B cell immunophenotype...
April 2016: Oncoimmunology
Susan Fajardo, Felicia Zook, Emily Dotson
PURPOSE: The oral oncology medications used in the treatment of chronic lymphocytic leukemia, chronic myeloid leukemia, multiple myeloma, and non-Hodgkin's lymphoma are reviewed, and the specialty pharmacy services at three large academic medical centers are described. SUMMARY: More than one dozen oral oncology medications are being used for hematologic malignancies and afford patients increased convenience and the potential to improve their quality of life. These agents include ibrutinib, idelalisib, imatinib, dasatinib, nilotinib, bosutinib, ponatinib, thalidomide, lenalidomide, pomalidomide, panobinostat, ixazomib, and vorinostat...
June 1, 2016: American Journal of Health-system Pharmacy: AJHP
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"